DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

[News]

DARA BioSciences, Inc., a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for KRN5500, a compound in development to treat a painful form of chronic chemotherapy-induced peripheral neuropathy (CCIPN).

More... (http://www.news-medical.net/news/20121130/DARA-BioSciences-submits-KRN5500-Orphan-Drug-Application-with-FDA.aspx)